BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/20/2017 8:47:00 AM | Browse: 856 | Download: 1392
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 28219
Country United Kingdom
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
Manuscript Source Invited Manuscript
All Author List Esther Una Cidon
Funding Agency and Grant Number
Corresponding Author Esther Una Cidon, MD, PhD, Medical Oncologist, Department of Medical Oncology, Royal Bournemouth Hospital, Castle Lane East, Castle Ln E, Bournemouth BH5 2AZ, United Kingdom. aunacid@hotmail.com
Key Words Gastroenteropancreatic neuroendocrine tumors; Peptide receptor radionuclide therapy; Soma­tostatin analogs; Octreotide; Transarterial chemoemboli­zation; Carcinoid syndrome; Setotonin; Chromogranin
Core Tip The management of localized NETs is straight forward, however, the treatment of advanced tumors involves several disciplines and requires a coordinated multidisciplinary approach. Recent advances in molecular biology have expanded the therapeutic arsenal. Somatostatin analogs, initially approved for control of hormonal syndromes, have recently proven to inhibit tumor growth. Several new drugs, antiangiogenics, mTOR inhibitors have been tested with promising results and some of them have already been approved. Several trials are still under way but the future should focus on patient selection, predictive markers, and tolerability improvement as critical aspects to continue advancing.
Publish Date 2017-01-12 12:07
Citation Una Cidon E. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20
URL http://www.wjgnet.com/1948-5204/full/v9/i1/4.htm
DOI http://dx.doi.org/10.4251/wjgo.v9.i1.4
Full Article (PDF) WJGO-9-4.pdf
Full Article (Word) WJGO-9-4.doc